Di Che Pharmaceuticals: Intends to Sign Authorization License Agreement with AstraZeneca Involving $1.5 Billion.

Dicz Pharmaceuticals announced that the company plans to sign a "License Agreement" with AstraZeneca, granting it the exclusive rights to globally develop and commercialize Shuwozhe. The company will receive $600 million upfront, up to $400 million in clinical development milestone payments, up to $500 million in sales milestone payments, and royalty fees based on sales. AstraZeneca is a related party, making this transaction a related party transaction. The agreement will only take effect upon approval by the company's shareholders' meeting and relevant authorities.